Comparing Nihon Kohden (OTCMKTS:NHNKY) and Solana (NASDAQ:HSDT)

Solana (NASDAQ:HSDT) and Nihon Kohden (OTCMKTS:NHNKY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

Solana has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Nihon Kohden has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Earnings and Valuation

This table compares Solana and Nihon Kohden”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59 million	10.53	-$40.89 million	($109.67)	-0.02
Nihon Kohden	$1.56 billion	0.97	$95.79 million	$0.59	14.96

Nihon Kohden has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Solana and Nihon Kohden, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	1	1	2.50
Nihon Kohden	0	1	0	1	3.00

Solana currently has a consensus price target of $3.50, indicating a potential upside of 102.31%. Given Solana’s higher probable upside, analysts clearly believe Solana is more favorable than Nihon Kohden.

Profitability

This table compares Solana and Nihon Kohden’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Nihon Kohden	6.08%	9.46%	6.68%

Insider and Institutional Ownership

18.6% of Solana shares are held by institutional investors. Comparatively, 0.1% of Nihon Kohden shares are held by institutional investors. 14.4% of Solana shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nihon Kohden beats Solana on 8 of the 14 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About Nihon Kohden

Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.